Mansoor Raza Mirza
CIK: 0001588389
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- Jul 10, 2026SERA
SERA PROGNOSTICS, INC.
Award(A)Direct1.8K shares- - Jul 10, 2026SERA
SERA PROGNOSTICS, INC.
Award(A)Direct22.4K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)Direct38.8K shares- - Mar 1, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
174.1K shares- - Dec 5, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct292 shares at avg. $3.05$890.6 - Nov 5, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct221 shares at avg. $3.04$671.84 - Oct 6, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct227 shares at avg. $3.16$717.32 - Oct 1, 2025ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
225K shares- - Sep 5, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct222 shares at avg. $3.35$743.7 - Aug 5, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct225 shares at avg. $2.50$562.5 - Jul 7, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct234 shares at avg. $2.36$552.24 - Jun 6, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct107 shares at avg. $1.58$169.06 - Jun 5, 2025SERA
SERA PROGNOSTICS, INC.
Award(A)Direct15.6K shares- - May 28, 2025KPTI
Karyopharm Therapeutics Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
4.6K shares- - May 8, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct106 shares at avg. $2.44$258.64 - Apr 7, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct107 shares at avg. $3.35$358.45 - Mar 6, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct99 shares at avg. $4.16$411.84 - Feb 12, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct101 shares at avg. $4.58$462.58 - Jan 27, 2025SERA
SERA PROGNOSTICS, INC.
Exercise(M)Direct37.5K shares at avg. $0.91$34K - Jan 6, 2025SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct100 shares at avg. $7.69$769 - Dec 6, 2024SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct93 shares at avg. $7.12$662.16 - Nov 11, 2024SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct95 shares at avg. $7.32$695.4 - Oct 7, 2024SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct96 shares at avg. $7.15$686.4 - Sep 6, 2024SERA
SERA PROGNOSTICS, INC.
Sale(S)Direct96 shares at avg. $7.16$687.36
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 10, 2026 |  SERA SERA PROGNOSTICS, INC. | Award(A) | 1,771 | - | $0 | Direct |
| Jul 10, 2026 | SERA SERA PROGNOSTICS, INC. | Award(A) | 22,426 | - | $0 | Direct |
| May 18, 2026 |  ACRV Acrivon Therapeutics, Inc. | Award(A) | 38,817 | - | $0 | Direct |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 174,068 | - | - | Direct |
| Dec 5, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 292 | $3.05 | $891 | Direct |
| Nov 5, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 221 | $3.04 | $672 | Direct |
| Oct 6, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 227 | $3.16 | $717 | Direct |
| Oct 1, 2025 | ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 225,000 | - | - | Direct |
| Sep 5, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 222 | $3.35 | $744 | Direct |
| Aug 5, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 225 | $2.50 | $563 | Direct |
| Jul 7, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 234 | $2.36 | $552 | Direct |
| Jun 6, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 107 | $1.58 | $169 | Direct |
| Jun 5, 2025 | SERA SERA PROGNOSTICS, INC. | Award(A) | 15,596 | - | - | Direct |
| May 28, 2025 |  KPTI Karyopharm Therapeutics Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 4,600 | - | - | Direct |
| May 8, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 106 | $2.44 | $259 | Direct |
| Apr 7, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 107 | $3.35 | $358 | Direct |
| Mar 6, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 99 | $4.16 | $412 | Direct |
| Feb 12, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 101 | $4.58 | $463 | Direct |
| Jan 27, 2025 | SERA SERA PROGNOSTICS, INC. | Exercise(M) | 37,549 | $0.91 | $34,170 | Direct |
| Jan 6, 2025 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 100 | $7.69 | $769 | Direct |
| Dec 6, 2024 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 93 | $7.12 | $662 | Direct |
| Nov 11, 2024 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 95 | $7.32 | $695 | Direct |
| Oct 7, 2024 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 96 | $7.15 | $686 | Direct |
| Sep 6, 2024 | SERA SERA PROGNOSTICS, INC. | Sale(S) | 96 | $7.16 | $687 | Direct |
1-24 of 24 transactions
About Mirza Mansoor Raza
Mirza Mansoor Raza (SEC CIK 0001588389) files insider reports with the SEC as Director of SERA PROGNOSTICS, INC. (SERA), Chief Medical Officer of Acrivon Therapeutics, Inc. (ACRV) and Director of Karyopharm Therapeutics Inc. (KPTI).
Signal8 holds 23 ownership filings by Mirza Mansoor Raza (1 Form 3, 22 Form 4), filed between Sep 9, 2024 and Jul 14, 2026. Those filings report 24 transactions, from Sep 6, 2024 to Jul 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mirza Mansoor Raza's filings is in SALT LAKE CITY, UT.
Recent filings by Mirza Mansoor Raza
- Jul 10, 2026: Grants or awards of SERA shares (2 lines, Form 4, code A).
- May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
- Mar 1, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
- Dec 5, 2025: Open-market sale of SERA shares (Form 4, code S).
- Nov 5, 2025: Open-market sale of SERA shares (Form 4, code S).
Other insiders filing for SERA PROGNOSTICS, INC. (SERA)
- Inglis Tiffany Eul Davis, Chief Medical Officer
- Anderson Dyaarl Lee Jr., Chief Commercial Officer
- Lindgardt Zhenya, Chief Executive Officer
- Jackson Benjamin, General Counsel
- Aerts Austin, Chief Financial Officer
- Gleason Scott, Chief Financial Officer